SCHEMBL7182853

SCHEMBL7182853

COc1cccc(Cl)c1C(=O)Pc1ccc(OC(C)C)cc1C.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PNLIP P16233 1/20 0.36
LMNA P02545 3/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 4/20 0.36
BRPF1 P55201 1/20 0.36
ALDH1A1 P00352 4/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA14 Q9ULX7 1/20 0.35
HPGD P15428 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
P2RX7 Q99572 2/20 0.35
GAA P10253 1/20 0.35
CXCL12 P48061 1/20 0.34
HCRTR1 O43613 1/20 0.34
HCRTR2 O43614 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7183348 0.93 CA12 (0.39) LMNAHTTMAPTBRPF1ALDH1A1
SCHEMBL7187692 0.93 ALDH1A1 (0.38) LMNAHTTMAPTALDH1A1HPGD
SCHEMBL7182596 0.91 MAPT (0.43) PNLIPLMNAMAPTALDH1A1CA12
Lithium SCHEMBL7190318 0.90 MAPT (0.35) PNLIPLMNAMAPTBRPF1ALDH1A1
SCHEMBL7183497 0.90 BRPF1 (0.39) PNLIPLMNAMAPTBRPF1ALDH1A1
SCHEMBL7177496 0.90 TYK2 (0.37) LMNAMAPTALDH1A1HPGDGAA
SCHEMBL7185567 0.89 HDAC1 (0.35) LMNAMAPTALDH1A1L3MBTL1GAA
Lithium SCHEMBL7183504 0.87 BRPF1 (0.39) PNLIPLMNAMAPTBRPF1ALDH1A1
SCHEMBL7175607 0.87 MAPT (0.39) MAPTALDH1A1L3MBTL1GAASMN1; SMN2
SCHEMBL7189833 0.85 MAPT (0.41) HTTMAPTALDH1A1GAAPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 PNLIP 1717/4885LMNA 3241/4885HTT 2802/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 PNLIP 1204/4885LMNA 3247/4885HTT 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.